Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Share:
Related MD
US Stock Futures Edge Lower Ahead Of ADP Report
MEDNAX Announces Acquisition of Pediatric Ear, Nose and Throat Practice in Houston
Mednax beats by $0.02, misses on revenue (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

DateFirmActionFromTo
May 2015Raymond JamesMaintainsOutperform
Feb 2015Stifel NicolausUpgradesHoldBuy
Jan 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MD)

Get Benzinga's Newsletters